Preliminary results from a randomized, open-label, phase 2 study of botensilimab (BOT) with or without balstilimab (BAL) in refractory microsatellite stable metastatic colorectal cancer with no liver metastases (MSS mCRC NLM) Meeting Abstract
| Authors: | Fakih, M.; Segal, N. H.; Schlechter, B. L.; Andre, T.; Pietrantonio, F.; Johnson, B.; Vasilyev, A.; Krishnamurthi, S. S.; Siena, S.; Messersmith, W. A.; Souza E Silva, V.; Paulson, A. S.; Elez, E.; Eng, C.; Tejpar, S.; Ducreux, M. P.; Wu, W.; Grossman, J. E.; Van Cutsem, E.; Hidalgo, M. |
| Abstract Title: | Preliminary results from a randomized, open-label, phase 2 study of botensilimab (BOT) with or without balstilimab (BAL) in refractory microsatellite stable metastatic colorectal cancer with no liver metastases (MSS mCRC NLM) |
| Meeting Title: | 2025 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2025 Jan 23-25 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-02-01 |
| DOI: | 10.1200/JCO.2025.43.4_suppl.23 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl plus with full text |
| DOI/URL: | |
| Notes: | Meeting Abstract: 23 -- Source: CINAHL Plus with Full Text |
